BSEN627

BSEN627 is an investigational **small-molecule ion channel modulator** being developed by Bsense Bio Therapeutics for sensory hyperexcitability disorders, with preclinical work particularly focused on **pain** and neuralgia. Available descriptions indicate that it acts through a multimodal ion-channel mechanism that includes **activation of Kv7.2 and Kv7.3 potassium channels** and **antagonism of TRPV1**, a profile intended to reduce neuronal hyperexcitability and nociceptive signaling. Publicly available reports describe positive preclinical proof-of-concept data in chronic neuropathic pain models, including comparison with pregabalin, but there is no clear evidence from the retrieved sources of clinical approval or established marketed use.